Here, we first tested if lovastatin improved the in vivo antitumor efficacy of AdE4 or AdE4-TRAIL in PSA/PSMA positive, androgen-independent CWR22rv subcutaneous tumor xenografts in nude mice. Here, FOLH1 is linked to neoplasm.